Skip to main content

Wayrilz

Pronunciation: WAY-rilz
Generic name: rilzabrutinib
Dosage form: tablets (400 mg)

Medically reviewed by Melisa Puckey, BPharm. Last updated on Sep 4, 2025.

What is Wayrilz?

Wayrilz is a prescription medicine used to treat persistent or chronic immune thrombocytopenia (ITP) in adults who have not responded sufficiently to earlier treatments. Wayrilz is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that addresses the root causes of ITP, which results in rapid and sustained platelet counts and improvements in other ITP symptoms. Wayrilz is an oral tablet taken twice daily.

Immune thrombocytopenia (ITP) is an autoimmune disorder where the body’s immune system mistakenly targets and destroys its own platelets, which are important for blood clotting.

Wayrilz's mechanism of action is as a Bruton’s tyrosine kinase (BTK) inhibitor, which has an immune-modulating therapeutic effect. It inhibits B cell activation, reducing the generation of autoantibodies that target platelets, and reduces platelet destruction by interrupting antibody-coated cell phagocytosis by Fcγ receptor (FcγR) in spleen and liver.

Wayrilz (rilzabrutinib) FDA approval was granted on August 29, 2025 LUNA 3 phase 3 study (NCT04562766), showed a positive impact on sustained platelet counts and other ITP symptoms.

Side effects 

The most common Wayrilz side effects are: 

Serious side effects and warnings

Wayrilz may cause serious side effects, including:  

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking this medicine

Before taking Wayrilz, tell your healthcare provider about all of your medical conditions, including if you:  

Pregnancy 

Tell you healthcare providers if you are pregnant or plan to become pregnant. Wayrilz may harm your unborn baby. If you are able to have a baby, your healthcare provider will do a pregnancy test before starting treatment withthis medicine. 

Females who are able to become pregnant should use effective birth control (contraception) during treatment with this medicine and for 1 week after the last dose.  

Breastfeeding

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if WAYRILZ passes into your breast milk. Do not breastfeed during treatment with Wayrilz and for at least 1 week after the last dose. 

How should I take this medicine?  

Take Wayrilz exactly as your healthcare provider tells you to take it.  Do not change your dose or stop taking these tablets unless your healthcare provider tells you to.  

Wayrilz Dosing information

Usual Recommended dose: 400 mg twice daily

What happens if I miss a dose?

If you miss a dose of Wayrilz, take the missed dose as soon as you remember on the same day and at least 2 hours apart from the next regular scheduled dose.  If you take too much WAYRILZ, call your healthcare provider or Poison Help Line at 1-800-222-1222. 

What should I avoid while taking this medicine?

You should avoid grapefruit, starfruit, and products that have these fruits, and Seville oranges (often used in marmalades) during treatment with Wayrilz. These products may increase the amount of the active ingredients rilzabrutinib in your blood, which increases the risk of side effects of Wayrilz.

What other drugs will affect Wayrilz?

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking Wayrilz with certain other medicines may affect how it works and can cause side effects. Wayrilz may also affect how other medicines work. Know the medicines you take and keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. 

Avoid using Wayrilz with:

 Wayrilz should be administered at least 2 hours before taking an antacid or H2 receptor antagonist. 

This is not a complete list of interactions. See the Wayrilz Prescribing Information for a complete list.

Storage 

Store at room temperature between 20°C to 25°C (68°F to 77°F) in the original packaging.  

Protect from light and moisture. 

Ingredients

Active ingredients: rilzabrutinib 

Inactive ingredients: 

Company

Genzyme Corporation Cambridge, MA 02141 A SANOFI COMPANY 

More about rilzabrutinib

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.